Associated Papers
Association of UGT1A9 Polymorphisms with Cardiac Injury Biomarkers and Clinical Features.
Özen M et al.
Pharmaceuticals (basel, Switzerland), 2025
Impact of genetic variations on the pharmacokinetics, dose requirements, and clinical effects of propofol: a systematic review.
Gerstman MD et al.
British Journal of Anaesthesia, 2025
Dolutegravir metabolism: impact of genetic variations on uridine diphosphate glucuronosyltransferase subfamilies.
Tagawa K et al.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems, 2025
The landscape of rare genetic variants in familial Waldenström macroglobulinemia.
Pemov A et al.
Blood Neoplasia, 2024
APF2: an improved ensemble method for pharmacogenomic variant effect prediction.
Zhou Y et al.
The Pharmacogenomics Journal, 2024
Effect of CYB2B6 (c.516G>T), CYP2C9 (c.1075A>C) and UGT1A9 (c.98T>C) polymorphisms on propofol pharmacokinetics in patients submitted to colonoscopy: a cohort study.
Poma MAM et al.
Postgraduate Medical Journal, 2023
Effects of common genetic variants of human uridine diphosphate glucuronosyltransferase subfamilies on irinotecan glucuronidation.
Tagawa K et al.
Toxicology Mechanisms and Methods, 2023
Loss of Function ABCG2 c.421C>A (rs2231142) Polymorphism Increases Steady-State Exposure to Mycophenolic Acid in Stable Renal Transplant Recipients: An Exploratory Matched Cohort Study.
Borić-Bilušić AA et al.
Advances in Therapy, 2023
Exome-wide association analysis of CT imaging-derived hepatic fat in a medical biobank.
Park J et al.
Cell Reports. Medicine, 2022
Common UGT1A6 Variant Alleles Determine Acetaminophen Pharmacokinetics in Man.
Cerezo-Arias MLO et al.
Journal of Personalized Medicine, 2022
Effect of CYB2B6 (c.516G>T), CYP2C9 (c.1075A>C) and UGT1A9 (c.98T>C) polymorphisms on propofol pharmacokinetics in patients submitted to colonoscopy: a cohort study.
Poma MAM et al.
Postgraduate Medical Journal, 2022
Common UGT1A9 polymorphisms do not have a clinically meaningful impact on the apparent oral clearance of dapagliflozin in type 2 diabetes mellitus.
Naagaard MD et al.
British Journal of Clinical Pharmacology, 2022
GABRA1 and GABRB2 Polymorphisms are Associated with Propofol Susceptibility.
Zeng Y et al.
Pharmacogenomics and Personalized Medicine, 2022
Clinical Importance of Potential Genetic Determinants Affecting Propofol Pharmacokinetics and Pharmacodynamics.
Budic I et al.
Frontiers in Medicine, 2022
Worsening of Kidney Transplant Function During 2-Year Follow-up Is Associated With the Genetic Variants of CYP3A4, MDR1, and UGT1A9.
Hryniewiecka E et al.
Transplantation Proceedings, 2020
UGT1A3 and Sex Are Major Determinants of Telmisartan Pharmacokinetics-A Comprehensive Pharmacogenomic Study.
Hirvensalo P et al.
Clinical Pharmacology and Therapeutics, 2020
Pharmacokinetics and pharmacogenomics of mycophenolic acid and its clinical correlations in maintenance immunosuppression for lupus nephritis.
Yap DYH et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association, 2020
The Effect of UGT1A9, CYP2B6 and CYP2C9 Genes Polymorphism on Propofol Pharmacokinetics in Children.
Pavlovic D et al.
Pharmacogenomics and Personalized Medicine, 2020
An optimized prediction framework to assess the functional impact of pharmacogenetic variants.
Zhou Y et al.
The Pharmacogenomics Journal, 2019
Multiplex analysis of genetic polymorphisms within UGT1A9, a gene involved in phase II of Δ9-THC metabolism.
Schneider JS et al.
International Journal of Legal Medicine, 2019
Influence of uridine diphosphate-glucuronosyltransferases (1A9) polymorphisms on mycophenolic acid pharmacokinetics in patients with renal transplant.
Ciftci HS et al.
Renal Failure, 2018
Regression and Genomic Analyses on the Association Between Dose-Normalized Mycophenolic Acid Exposure and Absolute Neutrophil Count in Steroid-Free, De Novo Kidney Transplant Recipients.
Kiang TKL et al.
Clinical Drug Investigation, 2018
Individualization of Irinotecan Treatment: A Review of Pharmacokinetics, Pharmacodynamics, and Pharmacogenetics.
de Man FM et al.
Clinical Pharmacokinetics, 2018
Pharmacogenomics in Papua New Guineans: unique profiles and implications for enhancing drug efficacy while improving drug safety.
Tucci JD et al.
Pharmacogenetics and Genomics, 2018
Longrange PCR-based next-generation sequencing in pharmacokinetics and pharmacodynamics study of propofol among patients under general anaesthesia.
Zakerska-Banaszak O et al.
Scientific Reports, 2017
The regioselective glucuronidation of morphine by dimerized human UGT2B7, 1A1, 1A9 and their allelic variants.
Yang ZZ et al.
Acta Pharmacologica Sinica, 2017
Study on the association of UGT1A9 gene c.98T>C polymorphism and mycophenolic acid plasma levels in renal transplant patients.
Ruschel LR et al.
Genetics and Molecular Research : Gmr, 2017
The effect of UGT1A9, CYP2B6 and CYP2C9 genes polymorphism on individual differences in propofol pharmacokinetics among Polish patients undergoing general anaesthesia.
Mikstacki A et al.
Journal of Applied Genetics, 2017
Prevalence of UDP-glucuronosyltransferase polymorphisms (UGT1A6∗2, 1A7∗12, 1A8∗3, 1A9∗3, 2B7∗2, and 2B15∗2) in a Saudi population.
Alkharfy KM et al.
Saudi Pharmaceutical Journal : Spj : the Official Publication of the Saudi Pharmaceutical Society, 2017
Inter-isoform Hetero-dimerization of Human UDP-Glucuronosyltransferases (UGTs) 1A1, 1A9, and 2B7 and Impacts on Glucuronidation Activity.
Yuan LM et al.
Scientific Reports, 2016
Dimerization of human uridine diphosphate glucuronosyltransferase allozymes 1A1 and 1A9 alters their quercetin glucuronidation activities.
Liu YQ et al.
Scientific Reports, 2016
Recipient uridine 5'-diphospho-glucuronosyltransferase UGT1A9 c.98T>C variant determines transplanted kidney filtration rate.
Pazik J et al.
Transplantation Proceedings, 2014
Genotype and allele frequencies of drug-metabolizing enzymes and drug transporter genes affecting immunosuppressants in the Spanish white population.
Bosó V et al.
Therapeutic Drug Monitoring, 2014
Genotype and allele frequencies of polymorphic UGT1A9 in the Polish population.
Zakerska O et al.
European Journal of Drug Metabolism and Pharmacokinetics, 2013
Genetic polymorphisms of UGT1A8, UGT1A9, UGT2B7 and ABCC2 in Chinese renal transplant recipients and a comparison with other ethnic populations.
Deng XY et al.
Die Pharmazie, 2013
Polymorphic expression of UDP-glucuronosyltransferase UGTlA gene in human colorectal cancer.
Wang M et al.
Plos One, 2013
Effects of amino acid substitutions at positions 33 and 37 on UDP-glucuronosyltransferase 1A9 (UGT1A9) activity and substrate selectivity.
Korprasertthaworn P et al.
Biochemical Pharmacology, 2012
UGT1A9, UGT2B7, and MRP2 genotypes can predict mycophenolic acid pharmacokinetic variability in pediatric kidney transplant recipients.
Fukuda T et al.
Therapeutic Drug Monitoring, 2012
Association of UDP-glucuronosyltransferase 1A9 polymorphisms with adverse reactions to catechol-O-methyltransferase inhibitors in Parkinson's disease patients.
Ferrari M et al.
European Journal of Clinical Pharmacology, 2012
Influence of sex on propofol metabolism, a pilot study: implications for propofol anesthesia.
Loryan I et al.
European Journal of Clinical Pharmacology, 2012
Early sorafenib-induced toxicity is associated with drug exposure and UGTIA9 genetic polymorphism in patients with solid tumors: a preliminary study.
Boudou-Rouquette P et al.
Plos One, 2012
Characterizing the effect of UDP-glucuronosyltransferase (UGT) 2B7 and UGT1A9 genetic polymorphisms on enantioselective glucuronidation of flurbiprofen.
Wang H et al.
Biochemical Pharmacology, 2011
The influence of pharmacogenetics and cofactors on clinical outcomes in kidney transplantation.
Picard N et al.
Expert Opinion on Drug Metabolism & Toxicology, 2011
Population pharmacokinetics and pharmacogenetics of mycophenolic acid following administration of mycophenolate mofetil in de novo pediatric renal-transplant patients.
Zhao W et al.
Journal of Clinical Pharmacology, 2010
Genetic polymorphism in metabolism and host defense enzymes: implications for human health risk assessment.
Ginsberg G et al.
Critical Reviews in Toxicology, 2010
[Pharmacogenomics for adverse drug reactions].
Saito Y et al.
Nihon Rinsho. Japanese Journal of Clinical Medicine, 2010